Simbolon Boyke Marthin, Yulizal O K, Hutapea Albert Manggading, Handoko Erwin
Faculty of Medicine, Universitas Prima Indonesia, Medan, Indonesia.
Department of Physiology, Universitas Advent Indonesi-a, Indonesia.
J Adv Vet Anim Res. 2024 Jun 6;11(2):284-290. doi: 10.5455/javar.2024.k774. eCollection 2024 Jun.
The present study investigated the effects of Andaliman fruit extract on tumor necrosis factor-alpha (TNF-α) and transient receptor potential ankyrin-1 (TRPA-1) levels in type 2 diabetes mellitus (T2DM) mouse models induced with streptozocin (STZ) and a high-fat diet (HFD).
In this research, mice were allocated into six distinct groups: normal, negative control (HFD and STZ), positive control (metformin, HFD, and STZ), and three treatment groups (HFD, STZ, and Andaliman extract at varying dosages of 100, 300, and 500 mg/kg, respectively). Body weight and blood glucose levels (BGLs) were recorded at weeks 1 (baseline), 8, 12, and 16. The levels of TNF-α and TRPA-1 were measured during the 16th week.
Phytochemical screening of the Andaliman extract revealed the presence of flavonoids, alkaloids, tannins, saponins, and glycosides. The one-way ANOVA revealed significantly elevated BGL at week 16 in the negative control group in comparison to the other groups ( < 0.05). The Kruskal-Wallis test followed by Bonferroni-corrected pairwise comparisons showed that the negative control had significantly higher TNF-α levels than the Andaliman-groups ( = 22.11, 001). TRPA-1 was significantly higher in the negative control group compared to the treatment groups ( < 0.05). Furthermore, Spearman's rho analysis revealed a statistically significant positive association between BGL and both TNF-α and TRPA-1, as well as between TNF-α and TRPA.
Andaliman extract potentially serves as a therapy for diabetic neuropathy in T2DM by lowering BGL and inhibiting the expression of TNF-α and TRPA-1.
本研究调查了山蒌果实提取物对链脲佐菌素（STZ）和高脂饮食（HFD）诱导的2型糖尿病（T2DM）小鼠模型中肿瘤坏死因子-α（TNF-α）和锚蛋白1型瞬时受体电位（TRPA-1）水平的影响。
在本研究中，小鼠被分为六个不同的组：正常组、阴性对照组（HFD和STZ）、阳性对照组（二甲双胍、HFD和STZ）以及三个治疗组（HFD、STZ和分别为100、300和500mg/kg不同剂量的山蒌提取物）。在第1周（基线）、第8周、第12周和第16周记录体重和血糖水平（BGL）。在第16周测量TNF-α和TRPA-1的水平。
山蒌提取物的植物化学筛选显示存在黄酮类、生物碱、单宁、皂苷和糖苷。单因素方差分析显示，与其他组相比，阴性对照组在第16周时BGL显著升高（<0.05）。Kruskal-Wallis检验及随后的Bonferroni校正的成对比较显示，阴性对照组的TNF-α水平显著高于山蒌提取物组（=22.11，<0.001）。与治疗组相比，阴性对照组的TRPA-1显著更高（<0.05）。此外，Spearman秩相关分析显示，BGL与TNF-α和TRPA-1之间以及TNF-α与TRPA之间存在统计学上显著的正相关。
山蒌提取物可能通过降低BGL以及抑制TNF-α和TRPA-1的表达，作为T2DM中糖尿病神经病变的一种治疗方法。
